Drug Interactions between diphtheria toxoid / haemophilus b conjugate (prp-omp) vaccine / hepatitis b pediatric vaccine / pertussis, acellular / poliovirus vaccine, inactivated / tetanus toxoid and teplizumab

ADJUST DOSING INTERVAL: The administration of inactivated, killed, mRNA or otherwise noninfectious vaccines during teplizumab therapy may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to six weeks after discontinuation of teplizumab therapy.

MANAGEMENT: According to the manufacturer of teplizumab, administration of inactivated, killed, or mRNA vaccinations is not recommended within the 2 weeks prior to, during, or for 6 weeks after treatment with teplizumab. Patients should be advised to receive all age-appropriate vaccinations prior to starting treatment with teplizumab.

ADJUST DOSING INTERVAL: The administration of inactivated, killed, mRNA or otherwise noninfectious vaccines during teplizumab therapy may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to six weeks after discontinuation of teplizumab therapy.

MANAGEMENT: According to the manufacturer of teplizumab, administration of inactivated, killed, or mRNA vaccinations is not recommended within the 2 weeks prior to, during, or for 6 weeks after treatment with teplizumab. Patients should be advised to receive all age-appropriate vaccinations prior to starting treatment with teplizumab.

ADJUST DOSING INTERVAL: The administration of inactivated, killed, mRNA or otherwise noninfectious vaccines during teplizumab therapy may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to six weeks after discontinuation of teplizumab therapy.

MANAGEMENT: According to the manufacturer of teplizumab, administration of inactivated, killed, or mRNA vaccinations is not recommended within the 2 weeks prior to, during, or for 6 weeks after treatment with teplizumab. Patients should be advised to receive all age-appropriate vaccinations prior to starting treatment with teplizumab.

ADJUST DOSING INTERVAL: The administration of inactivated, killed, mRNA or otherwise noninfectious vaccines during teplizumab therapy may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to six weeks after discontinuation of teplizumab therapy.

MANAGEMENT: According to the manufacturer of teplizumab, administration of inactivated, killed, or mRNA vaccinations is not recommended within the 2 weeks prior to, during, or for 6 weeks after treatment with teplizumab. Patients should be advised to receive all age-appropriate vaccinations prior to starting treatment with teplizumab.

ADJUST DOSING INTERVAL: The administration of inactivated, killed, mRNA or otherwise noninfectious vaccines during teplizumab therapy may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to six weeks after discontinuation of teplizumab therapy.

MANAGEMENT: According to the manufacturer of teplizumab, administration of inactivated, killed, or mRNA vaccinations is not recommended within the 2 weeks prior to, during, or for 6 weeks after treatment with teplizumab. Patients should be advised to receive all age-appropriate vaccinations prior to starting treatment with teplizumab.

ADJUST DOSING INTERVAL: The administration of inactivated, killed, mRNA or otherwise noninfectious vaccines during teplizumab therapy may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective during and for up to six weeks after discontinuation of teplizumab therapy.

MANAGEMENT: According to the manufacturer of teplizumab, administration of inactivated, killed, or mRNA vaccinations is not recommended within the 2 weeks prior to, during, or for 6 weeks after treatment with teplizumab. Patients should be advised to receive all age-appropriate vaccinations prior to starting treatment with teplizumab.